Russ Conroy

Pembrolizumab and mRNA-4157 demonstrated improvements in subgroups of resected melanoma, including those with BRAF-mutated tumors, in the phase 2 KEYNOTE-942 trial.

Progression-free survival in the central nervous system appears to be longer with trastuzumab deruxtecan than with comparator treatment in patients with HER2-positive metastatic breast cancer and brain metastases.

The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.

At the SOHO 2023 Annual Meeting, Mohammad Bakri Hammami, MD, spoke about the need to address disparities related to race, sex, and age among patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

Teclistamab plus talquetamab is the first-ever reported dual-specific bispecific combination in hematologic malignancies, says María-Victoria Mateos, MD, PhD.

Eftilagimod alpha plus pembrolizumab showed an overall response rate of over 25% in patients with metastatic head and neck squamous cell carcinoma treated in the phase 2 TACTI-002 study.

Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.

Nivolumab and sunitinib combined in the first-line treatment continues to maintain benefit for patients with advanced or metastatic renal cell carcinoma.

New findings from the phase 2 INFINITY trial shows promise for tremelimumab and durvalumab in patients with gastric/GEJ adenocarinoma.

Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.